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Cost-effectiveness of ACE inhibitor therapy to prevent
dialysis in nondiabetic nephropathy: influence of the ACE
insertion/deletion polymorphism
Stefan Vegtera,b, Annalisa Pernad, Waˆtse Hiddemaa, Piero Ruggenentid,e,
Giuseppe Remuzzid,e, Gerjan Navisa,b and Maarten J. Postmaa,c
Introduction End-stage renal disease is associated with
high health-care costs and low quality of life compared
with chronic kidney disease. The renoprotective effectiveness
of angiotensin-converting enzyme inhibitors (ACEi) is
largely determined by the ACE insertion/deletion (I/D)
polymorphism. We determined the cost-effectiveness of
ACEi therapy in nondiabetic nephropathy for the ACE II/ID
and for the ACE DD genotype separately. Furthermore, we
considered a selective screen-and-treat strategy in which
patients are prescribed alternative, more effective, therapy
based on their ACE (I/D) polymorphism.
Methods Time-dependent Markov models were
constructed; cohorts of 1000 patients were followed for
10 years. Data were mainly gathered from the Ramipril
Efficacy In Nephropathy trial. Both univariate and
probabilistic sensitivity analyses were performed.
Results ACEi therapy dominated placebo in both the ACE
II/ID group (h15 826, and 0.091 quality-adjusted life years
gained per patient) and the ACE DD group (h105 104
and 0.553 quality-adjusted life years gained). Sensitivity
analyses showed 30.2% probability of ACEi being not
cost-effective in the ACE II/ID group, against an almost
100% probability of cost-effectiveness in the ACE DD
group. A selective screen-and-treat strategy should
incorporate an alternative therapy for patients with the ACE
II/ID genotype with an at least 9.1% increase in survival
time compared with ACEi therapy to be cost-effective.
Sensitivity analyses show that higher effectiveness
and lower costs of the alternative therapy improve
the cost-effectiveness of a screening strategy.
Conclusion ACEi therapy is a cost-saving treatment
compared with placebo in nondiabetic nephropathy,
irrespective of ACE (I/D) genotype. However, ACEi therapy
saved more costs and more health gains were achieved
in the ACE DD genotype than in the ACE II/ID genotype.
An alternative treatment featuring a modest increase in
effectiveness compared with ACEi therapy for patients
with the ACE II/ID genotype can be incorporated in a
cost-effective or even cost-saving screen-and-treat strategy.
Pharmacogenetics and Genomics 19:695–703 c 2009
Wolters Kluwer Health | Lippincott Williams & Wilkins.
Pharmacogenetics and Genomics 2009, 19:695–703
Keywords: angiotensin-converting enzyme inhibitors, chronic kidney failure,
cost-effectiveness analysis, end-stage renal disease, genetic polymorphism
Departments of aPharmacy, Unit of PharmacoEpidemiology and PharmacoEconomics
(PE2), University of Groningen, bInternal Medicine, Division of Nephrology,
cEpidemiology, University Medical Centre Groningen (UMCG), Groningen,
The Netherlands, dClinical Research Centre for Rare Diseases ‘Aldo e Cele Dacco`’,
Mario Negri Institute for Pharmacological Research, Bergamo, Italy and eUnit of
Nephrology, Azienda Ospedaliera Ospedali Riuniti di Bergamo, Bergamo, Italy
Correspondence to Stefan Vegter, MSc, Department of Pharmacy, Unit of
PharmacoEpidemiology and PharmacoEconomics (PE2), Antonius Deusinglaan 1,
Groningen 9713 AV, The Netherlands
Tel: + 31 50 363 8204; fax: + 31 50 363 2772; e-mail: s.vegter@rug.nl
Received 11 November 2008 Accepted 6 July 2009
Introduction
Chronic kidney disease (CKD) is characterized by a
decline in renal function, which may ultimately lead to
end-stage renal disease (ESRD). Diabetes mellitus (DM)
is one of the leading causes of CKD and subsequent
ESRD. The European Renal Association-European Dia-
lysis and Transplant Association reported that in Europe,
prevalence of ESRD caused by DM type 1 or DM
type 2 rose from 51.5 to 94.8 per million between 1992 and
2000 [1]. The prevalence of ESRD of nondiabetic origin
rose from 455.8 to 607.2 per million in the same time
period [1]. In The Netherlands, 3 095 patients suffered
from ESRD of nondiabetic origin in 2008 [2].
Medical treatment modalities for ESRD patients include
haemodialysis, peritoneal dialysis and renal transplantation;
with haemodialysis being the most and renal transplanta-
tion the least common modality [2]. Several studies have
assessed the quality of life (QoL) of ESRD patients,
invariably showing a considerably lower QoL in ESRD
patients compared with CKD patients [3]. Costs of
ESRD treatment modalities are high, with a share of the
national expenditures in European countries ranging from
0.7% in the UK to 1.8% in Belgium (1.5% in France, 1.6%
in Italy) [4]. Therefore, to delay or prevent the onset
of ESRD is an important clinical goal.
ACEi efficacy and influence of the ACE (I/D)
polymorphism
The renoprotective efficacy of angiotensin-converting
enzyme inhibitors (ACEi) is undisputed. ACEi have been
shown to delay the onset of ESRD in diabetic as well
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as nondiabetic nephropathy [5,6]. However, individual
differences in therapy response are large [7]. An
important factor influencing ACEi efficacy is a poly-
morphism located in the ACE gene. This polymorphism
was first described by Rigat et al. in 1990 [8] and is based
on the presence (insertion, I) or absence (deletion, D) of
a 287 base pair element in intron 16 of the ACE gene.
A recent review presented an overview of the main
studies evaluating the relationship between the ACE
genotype and response to ACEi in nondiabetic renal
disease [9]. The Ramipril Efficacy In Nephropathy
(REIN) trial was the largest trial in terms of patient
numbers and duration, and crucially was the only study
that has used a hard endpoint, namely ESRD [5].
Patients with the ACE DD genotype showed increased
susceptibility for ACEi therapy [10,11]. The finding that
the ACE (I/D) polymorphism influences treatment
efficacy in nondiabetic nephropathy has boosted research
efforts for a treatment with increased effectiveness for
patients with the ACE II/ID genotype. Such a treatment,
incorporated in a selective screen-and-treat strategy,
would have a high probability of being cost-effective
or even cost saving, as the ACE II/ID genotype is
common and the costs and disease burden associated
with ESRD are high [12,13].
Study objectives
The importance of pharmacoeconomics for decision
making is increasing in all fields of health-care, in
particular regarding drug treatments. In that context it
is useful to know the cost-effectiveness of ACEi therapy
for the separate ACE (I/D) genotypes. Citing a checklist
from our group on performing pharmacoeconomic ana-
lyses on pharmacogenetic screening interventions, an
important starting point of such analyses is a compre-
hensive review of the evidence for the assumed associa-
tion between genotype and phenotype [12]. No selective
screen-and-treat strategy in nondiabetic nephropathy
based on the ACE (I/D) polymorphism existed at the
time, nor were studies found with conclusive evidence
for such a strategy. Therefore, our first study objective
was to understand the magnitude of difference in cost-
effectiveness of ACEi therapy in association with the
ACE genotype. In particular, we determined the cost-
effectiveness of ACEi therapy versus non-renin–angio-
tensin system acting antihypertensive drugs in non-
diabetic nephropathy separately for those with the ACE
DD genotype and those with the ACE II/ID genotype.
Our second study objective was to estimate cost-
effectiveness of a selective screen-and-treat strategy
involving an alternative treatment modality. By employing
a threshold analysis, we determined the increase in
effectiveness of an alternative treatment would require
compared with the existing ACEi treatment to justify a
screen-and-treat strategy, taking into account expected
additional costs and health effects. This analysis should
provide valuable information to researchers considering
new treatment modalities for nondiabetic nephropathy




Data from the REIN trial were used for this economic
analysis. The REIN trial was a randomized controlled trial
in nondiabetic nephropathy aimed at determining the
efficacy of the ACEi ramipril compared with placebo,
at the same level of blood pressure control [5]. The
REIN investigators found that the ACE (I/D) poly-
morphism was a strong predictor of ACEi efficacy;
progression to ESRD was considerably and significanlty
reduced in ACEi-treated compared with placebo-treated
patients with the ACE DD genotype (36% in placebo vs.
14% in ACEi), whereas a much smaller reduction was
found in those with the ACE II/ID genotype (23% in
placebo vs. 21% in ACEi) [10,11].
Models
Time-dependent Markov models were constructed with
three health-states: CKD, ESRD and death. Cohorts of
1 000 patients entered the model and were followed for a
time period of 10 years, and the health states were
determined on monthly cycles. Given this short cycle
time in the Markov model, no half-cycle correction was
used. Patients were not allowed to recover from ESRD by
reentering the CKD state.
Cost-effectiveness analysis of ACEi therapy
For the first study objective, the cost-effectiveness
of ACEi therapy was determined as compared with
placebo therapy. Cost-effectiveness was determined for
patients with the ACE II/ID and with the ACE DD
genotype separately.
Threshold analysis for the selective screen-and-treat
strategy
For our second study objective, we compared a selective
screen-and-treat strategy with the absence of screening.
For this goal, the Markov model was embedded in
a decision-tree analytical framework (Fig. 1). In the
nonscreening strategy, all patients received ACEi therapy.
In the screening strategy, the ACE (I/D) genotype of all
patients was screened; those with the ACE DD genotype
received ACEi therapy, whereas those with the ACE II/ID
genotype received an alternative renoprotective treat-
ment. As no preferred treatment over ACEi for patients
with ACE II/ID genotype currently exists, no prespeci-
fied effectiveness for this treatment was assumed.
Instead, a threshold analysis was performed in which
the effectiveness of the alternative treatment was
varied. The increase in effectiveness of the alternative
treatment compared with ACEi therapy needed for
a screen-and-treat strategy to become cost-effective
was determined.
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Model parameters
Five parametric survival distributions (Weibull, exponential,
lognormal, loglogistic and Gaussian) were fitted on the
REIN data by maximizing the likelihood ratio; the Akaike
information criterion (lower value indicates better fit)
was calculated for each distribution [14]. The effective-
ness of ACEi compared with placebo in our model was
based on the parameters of the best-fit distribution.
Mortality rates of patients with CKD were calculated
using data from the REIN and a similar trial in
nondiabetic nephropathy, REIN-2 [15]. In these trials,
nine deaths occurred over a cumulative follow-up of 1700
patient-years, resulting in an annual mortality rate of
0.53% per year [5,15]. Patients in the REIN trial were
followed until ESRD development or death [5]; therefore
no data on ESRD mortality were available. Mortality rates
of ESRD patients were instead derived from the Dutch
End-Stage Renal Disease Registry (RENINE), using
data from 1998 to 2008 [2]. No differences in mortality
rates between the ACE polymorphisms or treatment arms
were assumed.
ACE (I/D) polymorphism prevalences were derived from
several clinical trials in nondiabetic nephropathy
[10,11,16–20], all described in a systematic review by
Ruggenenti et al. [9]. QoL estimates were obtained
by examining a recently published systematic review [3],
in which one study was reported with QoL estimates for
CKD and ESRD based on community preferences, using
the Health Utilities Index-3 [21]. In economic evalua-
tions, community or societal preferences are preferred
over patient preferences [22].
A third-party payer perspective for the cost estimates
was adopted. Costs of ESRD were based on a weighted
average of Dutch cost estimates for active haemodialyses,
passive haemodialyses and peritoneal dialysis, adjusted
for inflation to 2008 values [23]. Costs of ramipril treat-
ment were based on 2008 Dutch prices [24], including
6% value-added tax and a 3-monthly pharmacists’
prescription fee of h6.10. In the REIN trial, ACEi
therapy was compared with placebo treatment; both
treatment arms received similar additional blood pressure
lowering drugs and health-care services [5]. Associated
health-care costs were equal in both groups and therefore
not included in our analysis. The costs of an alternative
treatment modality in the screening strategy were based
on Dutch prices for the new renin inhibitor aliskiren
[24], to reflect costs for a new treatment modality; these
costs were varied in sensitivity analyses. The price of a
genetic screening test for the ACE (I/D) polymorphism
was based on polymerase chain reaction and included
staff costs [25]. Costs and health effects were discounted
at 3% per annum, following recommendations by Gold
et al. [22] and Drummond et al. [26]. An overview of all
parameters is shown in Table 1.
Sensitivity analysis
Univariate and probabilistic sensitivity analyses were
performed for both the cost-effectiveness analysis
and the threshold analysis. In the univariate sensitivity
analyses, all model parameters were varied by 25% to
determine the main cost and effect drivers in our model.
Discount rates were varied based on Dutch guidelines for
pharmacoeconomic research recommending differential



















Decision tree model and Markov model; M represent the start of the Markov model, in which patients were followed for a time period of 10 years
and allowed to move from one state to another per month. ACEi, angiotensin-converting enzyme inhibitors; CKD, chronic kidney disease; ESRD,
end-stage renal disease.
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respectively [27,28]. Results of the univariate sensitivity
analysis are presented in a tornado diagram [29]. In the
probabilistic sensitivity analyses, triangular distributions
were used for all cost parameters; beta distributions for
ACE (I/D) genotype prevalences and QoL estimates; and
Poisson distributions for mortality probabilities. Variation
in ACEi effectiveness was captured by nonparametric
bootstrapping, in which a random sample of the same
size as the original data is drawn with replacement.
This procedure is performed a large number of times.
Bootstrapping is used to estimate the true distribution
of a sample regardless of the distribution of the orig-
inal data [29]. The probabilistic sensitivity analysis was
run 10 000 times.
Statistics
Fitting and bootstrapping of the REIN data were per-
formed in the statistical package R, version 2.5.1 [30].
The models and sensitivity analyses were constructed in
Microsoft Office Excel 2003.
Results
Five parametric distributions (Weibull, exponential,
lognormal, loglogistic and Gaussian) were fitted on the
REIN data. Akaike information criterion values and visual
assessment showed that the lognormal distribution
provided the best fit for both genotype groups and both
treatment arms. This distribution was therefore selected
for use in the Markov model.
Table 1 Parameters used in the analyses
Variable Baseline value Univariate sensitivity range Probabilistic sensitivity distribution Reference
Genotype prevalences
ACE DD prevalence 32.87% 24.65–41.08% Beta [10,11,16–20]
Costs
Dialysis (per year) h72354 h54265–h90443 Triangular [23]
ACEi therapy (per month) h3.03 h2.27–h3.79 Triangular [24]
Alternative therapy (per month) h23.67 h17.75–h29.59 Triangular [24]
Genetic screening test h50.00 h37.50–h62.50 Triangular [25]
Health effects
QoL chronic kidney disease 0.67 0.50–0.84 Beta [21]
QoL dialysis 0.54 0.41–0.68 Beta [21]
Annual mortality rate – CKD 0.53% 0.40%–0.66% Poisson [5,15]
Annual mortality rate – ESRD 9.95% 7.46%–12.44% Poisson [1]
ACEi effectiveness in ACE II/ID (days)a 15.3 11.5–19.1 Bootstrapping [11]
ACEi effectiveness in ACE DD (days)a 106.1 79.6–132.6 Bootstrapping [11]
Effectiveness of alternative treatment in
screening strategy (days)b
Varied in the threshold analysis
Ranges for univariate sensitivity analysis were ±25% for all parameters.
ACEi, angiotensin-converting enzyme inhibitor; CKD, chronic kidney disease; ESRD, end-stage renal disease; QoL, quality of life.
aEffectiveness of ACEi therapy was defined as prolongation of median time to ESRD compared with placebo.
bEffectiveness of the alternative treatment was defined as increase in effectiveness compared with ACEi therapy.
Table 2 Cost-effectiveness at baseline and probabilistic sensitivity analysis
Cost-effectiveness of ACEi therapy
ACEi therapy Placebo Cost-effectiveness of ACEi therapy
Costs QALYs Costs QALYs DCosts DQALYs Costs/QALY
Probability of
cost-effectiveness (%)a
All patients h115 826 5.130 h160789 4.887 h–45168 0.242 Dominance 97.6
ACE II/ID genotype
group
h125786 5.078 h141 612 4.988 h–15 826 0.091 Dominance 69.8
ACE DD genotype
group
h94860 5.235 h199963 4.682 h–105104 0.553 Dominance 99.8
Threshold analysis for the selective screen-and-treat strategy
Screening strategy Nonscreening strategy Cost-effectiveness of screening




h–44221 0.243 h–45 198 0.243 h977 0.000 Dominated 0
9.1% Increase in
effectivenessb
h–45 102 0.248 h–45 198 0.243 h96 0.005 h19 477 72.3
25% Increase in
effectivenessb
h–46 606 0.256 h–45 198 0.243 h–1408 0.013 Dominance 89.8
The term ‘dominance’ denotes that a strategy saves costs as well as QALYs compared with its comparator strategy (which is then said to be ‘dominated’).
ACEi, angiotensin-converting enzyme inhibitor; QALY, quality-adjusted life year.
aThe probability of cost-effectiveness was determined in the probabilistic sensitivity analysis.
bEffectiveness of the alternative treatment was defined as increase in effectiveness compared with ACEi therapy, which was defined as prolongation of median time
to ESRD compared with placebo.
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Cost-effectiveness of ACEi therapy
In the baseline analysis (Table 2), ACEi therapy
dominated placebo in both genotype groups, that is,
resulted in clinical benefits as well as cost-savings. In the
10-year time frame, cost savings for a patient with the
ACE II/ID genotype was h15 826 and h105 104 for a
patient with the ACE DD genotype. Overall, ACEi
therapy resulted in cost savings of h45 198. Quality-
adjusted life years (QALYs) gained per patient were
0.091 for a patient with the ACE II/ID genotype and
0.553 for ACE DD. Overall, ACEi therapy gained 0.243
QALYs per patient in the 10-year time frame.
Univariate sensitivity analysis showed that dialysis costs
and ACEi effectiveness had the largest influence on the
cost savings of ACEi therapy in both genotype groups
(Fig. 2a). The main drivers of health gains were QoL of
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(a and b) Univariate sensitivity analysis for net cost savings (a) and health gains (b) of angiotensin-converting enzyme inhibitors (ACEi) therapy; the
dashed line represents the baseline analysis. Black bars denote influence of the high end of the sensitivity range and grey bars denote influence
of the low end of the sensitivity range. Discounting rate was varied to 0% for both costs and health gains on the low end and 4 and 1.5% on the
high end for costs and health gains, respectively. CKD, chronic kidney disease; ESRD, end-stage renal disease; QALY, quality-adjusted life year;
QoL, quality of life.
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(Fig. 2b). Probabilistic sensitivity analysis (Fig. 3; Table 2)
showed that in the ACE II/ID genotype, ACEi therapy
has a 30.2% probability of resulting in an unfavourable
outcome (no health benefits or cost-effectiveness of
more than h20 000 /QALY). In the ACE DD genotype,
however, there was only a 0.2% probability of an
unfavourable cost-effectiveness outcome.
Threshold analysis for the selective screen-and-treat
strategy
A selective screen-and-treat strategy was based on the
decision-tree analytical framework and Markov model
(Fig. 1). The effectiveness of the alternative treatment
for ACE II/ID patients in the screening arm of this
strategy was varied in a threshold analysis. Results are
presented in Table 2. This analysis showed that an
alternative treatment should increase effectiveness
compared with ACEi therapy by 9.1% for a screening
strategy to be cost-effective compared with a nonscreening
strategy. Probabilistic sensitivity analysis showed that the
chance of cost-effectiveness under this assumption is
72.3%. With an increase in effectiveness of the alternative
treatment of 25%, a screening strategy would save
h1 408 and 0.013 QALY per patient, thus resulting in a
dominating strategy compared with nonscreening. The
chance of cost-effectiveness under this assumption
was 89.8%. When no increase in effectiveness of the
alternative treatment was assumed, a screening strategy
would generate extra costs and no health gains, thus
causing the screening strategy to be dominated by the
nonscreening strategy.
Univariate sensitivity analyses showed that the costs of
dialysis and of the alternative therapy were the most in-
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Two-way sensitivity analysis on the cost-effectiveness of a selective screen-and-treat strategy; dialysis costs and effectiveness of the alternative
treatment modality. Negative cost-effectiveness values denote cost-savings and health gains. QALY, quality-adjusted life year.
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estimates. Two-way analyses were performed for these
two variables and the effectiveness of the alternative
treatment (Figs 4 and 5). Lower costs of dialysis and
higher costs of the alternative treatment decreases the
cost-effectiveness of a screening strategy.
Discussion
This study showed that ACEi therapy is a cost-saving
treatment modality to prevent ESRD in nondiabetic
nephropathy irrespective of ACE genotype, based on the
Caucasian population of the REIN trial. However,
although ACEi is cost saving for all patients, there
are considerable differences in cost-effectiveness in the
different ACE (I/D) genotypes. ACEi therapy, compared
with non-renin–angiotensin system acting antihyper-
tensive drugs, resulted in more costs-savings and
more health gains in the ACE DD group than in the
ACE II/ID group. In addition, in the ACE II/ID genotype,
there was a 30.2% probability of ACEi therapy resulting
in an unfavourable cost-effectiveness outcome, while the
chance of ACEi therapy being cost-effective or even
cost saving in the ACE DD genotype was almost 100%.
Although separate analyses for the different polymorph-
isms have not been performed before, the finding
that ACEi therapy is a cost-effective treatment in non-
diabetic nephropathy has been reported in other studies.
Van Hout et al. [31] analyzed ACEi cost-effectiveness
based on the ACE Inhibition in the Progressive Renal
Insufficiency trial, and found ACEi therapy to save
$28 014 per patient, using a time frame of 10 years (in
1996 US$, equivalent to h30 272 in 2008 price levels).
Ruggenenti et al. [32] performed a cost-effectiveness
analysis based on the REIN trial and found ACEi therapy
to save between $16 605 and $23 894 per lifetime (in
2000 US$, equivalent to h20 887 and h30 056 in 2008
price levels). Scha¨dlich et al. [33] reported cost savings
between 76 700 and 81 900 Deutschmarks per patient-
year of chronic dialysis avoided, using a time frame of
1–3 years (in 1999 Deutschmarks, equivalent to h51 168
and h54 637 in 2008 price levels). Our model demon-
strated cost savings of ACEi therapy compared with
placebo of h45 198 per patient using a 10-year time frame
(ACE II/ID and ACE DD combined). Overall, cost
savings per patient-year of chronic dialysis avoided were
h60 597. The larger cost savings in our study compared
with previous studies can be explained by lower
discounting rates and higher costs of dialysis assumed
in our model compared with the other studies.
The main limitation of this study is the assumption of an
association between the ACE (I/D) polymorphism and
ACEi therapy response, which is still disputed. In fact,
several studies reported that the D allele is associated
with ACEi therapy resistance [16,19], contrary to our
model assumptions. The trial used for our analyses was
the only trial evaluating a hard endpoint, namely ESRD.
A recent analysis in one of the contradicting trials [19]
showed that the preintervention rate of renal function
loss (measured as creatinine clearance) was significantly
higher in the ACE DD group compared with the other
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Two-way sensitivity analysis on the cost-effectiveness of a selective screen-and-treat strategy; costs and effectiveness of the alternative treatment
modality. Negative cost-effectiveness values denote cost savings and health gains. QALY, quality-adjusted life year.
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into account, ACEi therapy did in fact benefit patients
with the ACE DD genotype, but not those with ACE II/
ID genotype [34]. Therefore, although the REIN trial
was the largest trial on the subject, other studies seem to
confirm the findings. However, environmental factors
should also be considered when determining the associa-
tion between ACE genotype and ACEi response. ACEi
therapy response is also dependent on sodium status,
with more effective response on low sodium excretion in
the ACE DD genotype [17].
We employed a third-party perspective for our cost
estimates as opposed to a societal perspective. Although
many guidelines recommend adoption of a societal
perspective, for a first assessment of the cost-effec-
tiveness of genetic screening interventions, there are
limitations in performing this in our case because of a lack
of data in developmental stages and data being
based on efficacy as opposed to real-life effectiveness
[12]. In addition, the third-party focus is often of prime
interest to payer decision makers. However, for full
understanding of the economic impact, indirect costs
should be considered before final decisions on imple-
mentations of screening strategies are made [12].
The models and parameters used in this economic
analysis have been kept as relevant and transparent
as possible. However, as in all economic analyses, several
assumptions and estimates were made. Sensitivity
analyses showed that mortality rates had a minor
influence of the cost-effectiveness of the treatment
modalities. Mortality rates in CKD were estimated from
data obtained from the REIN and REIN-2 study
combined. Mortality rates in ESRD were assumed to be
similar in both ACE genotype groups. There is evidence
that mortality is higher in dialysis patients with the ACE
DD genotype [35]; however no information on ACEi
therapy versus other antihypertensive drugs was reported.
The most influential factor in sensitivity analyses was the
cost of dialysis. When higher dialysis costs were assumed,
ACEi therapy became more cost-effective in both ACE
genotypes. Cost-effectiveness of the selective screen-
and-treat strategy also increased with higher dialysis
costs, but was also dependent on the assumed effective-
ness and costs of the alternative treatment; these factors
should therefore be taken into account when developing
an alternative treatment to be employed in a selective
screen-and-treat strategy.
Conclusion
The ACE (I/D) polymorphism is a large determinant of
response to ACEi therapy not only in terms of health
outcomes but also of cost-effectiveness. This study
showed that ACEi therapy compared with placebo both
reduces costs and improves QALYs more in the ACE
DD group than in the ACE II/ID group, although
ACEi treatment remains cost saving in both genotypes.
A selective screen-and-treat strategy based on a treat-
ment modality, which produces a modest increase in
effectiveness in patients with the ACE II/ID genotype,
can result in large cost savings and clinical benefits.
Unfortunately, clinical evidence for such a selective
screen-and-treat strategy has been scarce and no such
strategy has yet been implemented in clinical practice.
Before this, ACEi therapy should be given to nondiabetic
nephropathy patients irrespective of ACE genotype. Still,
the large potential cost savings and clinical benefits
associated with a selective screen-and-treat strategy
should ensure that studies and trials in this field remain
appealing for both researchers and decision makers.
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